PRMT5 and breast carcinoma: Thus, we sought to evaluate therapeutic opportunities for our PRMT5 inhibitors (C220 and PRT543) in ovarian and breast cancers, where PARP inhibitors are clinically approved in patients with HRD tumors (24, 25).